We have released our
2025 Impact Report

CSL is proud to strengthen our strategic partnership with leading Chinese pharmaceutical group Baheal Medical, reinforcing our long-term commitment to China’s healthcare market. Building on our collaboration since 2018, this alliance expands CSL’s coverage in both the retail and broader market segments, enabling us to reach more patients and elevate standards of specialty care. By combining CSL’s global expertise with Baheal’s commercialization strengths, we’re maximizing patient impact and supporting the “Healthy China 2030” initiative. Thank you to all teams for making this milestone possible. #CSL #China #PatientImpact

Faster. Smarter. More personal. Our new technology is transforming the plasma donation experience - cutting donation time by about one-third and helping donors do more good in less time. Because every donation helps create medicines that change lives. Read more in our impact report https://bit.ly/4nJqYd0 #CSL #CSLImpactReport #DonorExperience #Innovation #Patients

During CSL’s Capital Markets Day in the U.S., we shared how CSL is charting a path to deliver & create enduring patient impact and long-term value for shareholders. Core strength & future growth – Our immunoglobulin portfolio remains robust, with strong growth expected in the coming years. We also see significant opportunities beyond immunoglobulin, supported by innovative therapies and a pipeline designed to address unmet patient needs. Transformational change – Simplifying our business, refocusing R&D, optimising plasma operations, and integrating teams for greater efficiency. Thank you to all who joined us as we continue to deliver on our purpose: to save and improve lives. #CSL #CapitalMarketsDay #EnduringPatientImpact #Innovation #PatientsFirst

The stage is set in the U.S. for CSL’s bi-annual Capital Markets Day! Today, we welcome analysts and investors for a deep dive into our business - exploring strategy, performance and the science that drives our commitment to patients. Visit https://investors.csl.com for more information. #CSL

We are thrilled to be participating at the ASN Kidney Week 2025, taking place in Houston, Texas, November 5–9. This 5-day international meeting brings together over 12,000 kidney professionals from around the globe to share groundbreaking research, to explore the latest scientific advances, and to engage in thought-provoking discussions with leading experts in nephrology. We look forward to engaging with Health Care Professionals during ASN Kidney Week 2025. For more information on ASN Congress, visit https://bit.ly/47rI8Hr #ASNKidneyWeek #Nephrology #MedicalResearch #KidneyHealth #MedicalInnovation #ASN #cslvifor #cslbehring #csl

This week is PBM Awareness Week, highlighting the importance of Patient Blood Management \(#PBM \) in improving patient care and outcomes. CSL supports PBM – an approach endorsed by health authorities, including the World Health Organization, because it seeks to improve medical and patient outcomes by optimally managing and preserving a patient’s own blood. Practicing PBM means diagnosing and correcting #anemia and #irondeficiency , minimizing blood loss, and supporting the patient while appropriate treatment is initiated. At CSL, everything we do is driven by our promise to patients and we are committed to initiatives that improve and protect their health. That is why we are working with partners around the world to help advance the awareness, understanding and implementation of PBM. Implementing PBM is a win-win-win: better outcomes for patients, stronger health systems, and more sustainable care. Learn more on PBM here https://bit.ly/4i0Yj29 #PatientBloodManagementAwarenessWeek #CSL

Congratulations to Dr Carolien van de Sandt from MCRI in Melbourne who has been awarded a 2026 CSL Centenary Fellowship for her research on the challenge of immune system ageing, a key factor in vulnerability to viruses and declining vaccine effectiveness. Paying tribute to CSL’s Australian origins, the fellowships are an integral part of how CSL delivers on our promise to foster a thriving medical research community by supporting the advancement of Australian science. The $1.25 million CSL Centenary Fellowship will support Carolien’s next bold steps at the Murdoch Children’s Research Institute, where she will explore how, as we age, our T-cells become less effective at fighting acute viral infections and less flexible in responding to novel viruses. Read more: https://bit.ly/4339GQJ

Congratulations to Dr Rhys Grinter from Bio21 Institute, University of Melbourne, who has been awarded a 2026 CSL Centenary Fellowship. Dr Grinter is transforming drug development by harnessing Nobel Prize-winning AI technology, to engineer proteins. His innovative approach streamlines the production of natural proteins in the lab, delivering potential drugs many times faster than traditional methods. He will use his $1.25 million CSL Centenary Fellowship to develop a range of potential drugs to treat a range of diseases and conditions. Paying tribute to CSL’s Australian origins, the fellowships are an integral part of how CSL delivers on our promise to foster a thriving medical research community by supporting the advancement of Australian science. Read more: https://bit.ly/4hv3kPW

Two Australian scientists advancing research into life-long immunity and AI-designed proteins have each been awarded CSL Centenary Fellowships, valued at $1.25 million over five years. Dr Carolien van de Sandt’s fellowship supports her ground-breaking work on life-long immunity. She is tackling the challenge of immune system ageing - a key factor in vulnerability to viruses and declining vaccine effectiveness. The $1.25 million CSL Centenary Fellowship will support her next bold steps at the Murdoch Children's Research Institute (MCRI) , where she will explore how, as we age, our T-cells become less effective at fighting acute viral infections and less flexible in responding to novel viruses. Dr Rhys Grinter is transforming drug development by harnessing Nobel Prize-winning AI technology, to engineer proteins. His innovative approach streamlines the production of natural proteins in the lab, delivering potential drugs many times faster than traditional methods. He will use his $1.25 million CSL Centenary Fellowship to accelerate his research at Bio21 Institute, University of Melbourne where he hopes to develop a range of potential drugs to treat a range of diseases and conditions. The Fellowships were presented at the Australian Academy of Health and Medical Sciences Annual Meeting on Wednesday 29 October 2025 in Canberra. Read more: https://bit.ly/47kZ8xu #MedicalResearch #AustralianInnovation #AustralianMedicalResearch #CSLCentenaryFellowships #SupportingScience